Search

Your search keyword '"Hossain, Nasheed"' showing total 269 results
Start Over Author "Hossain, Nasheed"
269 results on '"Hossain, Nasheed"'

1. Trends in volumes and survival after hematopoietic cell transplantation in racial/ethnic minorities.

Author

Khera, Nandita, Ailawadhi, Sikander, Brazauskas, Ruta, Patel, Jinalben, Jacobs, Benjamin, Ustun, Celalettin, Ballen, Karen, Abid, Muhammad, Diaz Perez, Miguel, Al-Homsi, A, Hashem, Hasan, Hong, Sanghee, Munker, Reinhold, Schears, Raquel, Lazarus, Hillard, Ciurea, Stefan, Badawy, Sherif, Savani, Bipin, Wirk, Baldeep, LeMaistre, C, Bhatt, Neel, Beitinjaneh, Amer, Aljurf, Mahmoud, Sharma, Akshay, Cerny, Jan, Knight, Jennifer, Kelkar, Amar, Yared, Jean, Kindwall-Keller, Tamila, Winestone, Lena, Steinberg, Amir, Arnold, Staci, Seo, Sachiko, Preussler, Jaime, Hossain, Nasheed, Fingrut, Warren, Agrawal, Vaibhav, Hashmi, Shahrukh, Lehmann, Leslie, Wood, William, Rangarajan, Hemalatha, Saber, Wael, and Hahn, Theresa

Subjects
Humans, Hematopoietic Stem Cell Transplantation, Male, Female, Adult, Middle Aged, Ethnic and Racial Minorities, Adolescent, Child, Aged, Young Adult, Child, Preschool
Abstract

There has been an increase in volume as well as an improvement in overall survival (OS) after hematopoietic cell transplantation (HCT) for hematologic disorders. It is unknown if these changes have affected racial/ethnic minorities equally. In this observational study from the Center for International Blood and Marrow Transplant Research of 79 904 autologous (auto) and 65 662 allogeneic (allo) HCTs, we examined the volume and rates of change of autoHCT and alloHCT over time and trends in OS in 4 racial/ethnic groups: non-Hispanic Whites (NHWs), non-Hispanic African Americans (NHAAs), and Hispanics across 5 2-year cohorts from 2009 to 2018. Rates of change were compared using Poisson model. Adjusted and unadjusted Cox proportional hazards models examined trends in mortality in the 4 racial/ethnic groups over 5 study time periods. The rates of increase in volume were significantly higher for Hispanics and NHAAs vs NHW for both autoHCT and alloHCT. Adjusted overall mortality after autoHCT was comparable across all racial/ethnic groups. NHAA adults (hazard ratio [HR] 1.13; 95% confidence interval [CI] 1.04-1.22; P = .004) and pediatric patients (HR 1.62; 95% CI 1.3-2.03; P < .001) had a higher risk of mortality after alloHCT than NHWs. Improvement in OS over time was seen in all 4 groups after both autoHCT and alloHCT. Our study shows the rate of change for the use of autoHCT and alloHCT is higher in NHAAs and Hispanics than in NHWs. Survival after autoHCT and alloHCT improved over time; however, NHAAs have worse OS after alloHCT, which has persisted. Continued efforts are needed to mitigate disparities for patients requiring alloHCT.

Published
2024

2. Chimeric antigen receptor T-cell infusion for large B-cell lymphoma in complete remission: a center for international blood and marrow transplant research analysis

Author

Wang, Trent P., Ahn, Kwang W., Shadman, Mazyar, Kaur, Manmeet, Ahmed, Nausheen, Bacher, Ulrike, Cerny, Jan, Chen, Andy, Epperla, Narendranath, Frigault, Matthew, Grover, Natalie, Haverkos, Bradley, Hill, Brian, Hossain, Nasheed, Iqbal, Madiha, Jain, Tania, Krem, Maxwell M., Maakaron, Joseph, Modi, Dipenkumar, Alhaj Moustafa, Muhamad, Riedell, Peter, Savani, Bipin, Sica, R. Alejandro, Sureda, Anna, Wudhikarn, Kitsada, Herrera, Alex F., Sauter, Craig, Hamadani, Mehdi, and Jimenez Jimenez, Antonio

Published
2024
Full Text
View/download PDF

3. Autologous transplant vs. CAR-T therapy in patients with DLBCL treated while in complete remission

Author

Shadman, Mazyar, Ahn, Kwang W., Kaur, Manmeet, Lekakis, Lazaros, Beitinjaneh, Amer, Iqbal, Madiha, Ahmed, Nausheen, Hill, Brian, Hossain, Nasheed M., Riedell, Peter, Gopal, Ajay K., Grover, Natalie, Frigault, Matthew, Brammer, Jonathan, Ghosh, Nilanjan, Merryman, Reid, Lazaryan, Aleksandr, Ram, Ron, Hertzberg, Mark, Savani, Bipin, Awan, Farrukh, Khimani, Farhad, Ahmed, Sairah, Kenkre, Vaishalee P., Ulrickson, Matthew, Shah, Nirav, Kharfan-Dabaja, Mohamed A., Herrera, Alex, Sauter, Craig, and Hamadani, Mehdi

Published
2024
Full Text
View/download PDF

4. Impact of cytogenetic abnormalities on outcomes of adult Philadelphia-negative acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation: a study by the Acute Leukemia Working Committee of the Center for International Blood and Marrow Transplant Research

Author

Lazaryan, Aleksandr, Dolan, Michelle, Zhang, Mei-Jie, Wang, Hai-Lin, Kharfan-Dabaja, Mohamed A, Marks, David I, Bejanyan, Nelli, Copelan, Edward, Majhail, Navneet S, Waller, Edmund K, Chao, Nelson, Prestidge, Tim, Nishihori, Taiga, Kebriaei, Partow, Inamoto, Yoshihiro, Hamilton, Betty, Hashmi, Shahrukh K, Kamble, Rammurti T, Bacher, Ulrike, Hildebrandt, Gerhard C, Stiff, Patrick J, McGuirk, Joseph, Aldoss, Ibrahim, Beitinjaneh, Amer M, Muffly, Lori, Vij, Ravi, Olsson, Richard F, Byrne, Michael, Schultz, Kirk R, Aljurf, Mahmoud, Seftel, Matthew, Savoie, Mary Lynn, Savani, Bipin N, Verdonck, Leo F, Cairo, Mitchell S, Hossain, Nasheed, Bhatt, Vijaya Raj, Frangoul, Haydar A, Abdel-Azim, Hisham, Al Malki, Monzr, Munker, Reinhold, Rizzieri, David, Khera, Nandita, Nakamura, Ryotaro, Ringdén, Olle, Van der Poel, Marjolein, Murthy, Hemant S, Liu, Hongtao, Mori, Shahram, De Oliveira, Satiro, Bolaños-Meade, Javier, Elsawy, Mahmoud, Barba, Pere, Nathan, Sunita, George, Biju, Pawarode, Attaphol, Grunwald, Michael, Agrawal, Vaibhav, Wang, Youjin, Assal, Amer, Caro, Paul Castillo, Kuwatsuka, Yachiyo, Seo, Sachiko, Ustun, Celalettin, Politikos, Ioannis, Lazarus, Hillard M, Saber, Wael, Sandmaier, Brenda M, De Lima, Marcos, Litzow, Mark, Bachanova, Veronika, and Weisdorf, Daniel

Subjects
Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Cancer, Blood, Adult, Chromosome Aberrations, Hematopoietic Stem Cell Transplantation, Humans, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Cardiorespiratory Medicine and Haematology, Immunology, Cardiovascular medicine and haematology
Abstract

The authors inadvertently included grant numbers OT3HL147741 & U24CA233032, which are grant-specific. This was an oversight on the authors’ part as these grants did not support the research in this publication.

Published
2021

6. Myeloablative Conditioning for Allogeneic Transplantation Results in Superior Disease-Free Survival for Acute Myelogenous Leukemia and Myelodysplastic Syndromes with Low/Intermediate but not High Disease Risk Index: A Center for International Blood and Marrow Transplant Research Study.

Author

Bejanyan, Nelli, Zhang, Meijie, Bo-Subait, Khalid, Brunstein, Claudio, Wang, Hailin, Warlick, Erica, Giralt, Sergio, Nishihori, Taiga, Martino, Rodrigo, Passweg, Jakob, Dias, Ajoy, Copelan, Edward, Hale, Gregory, Gale, Robert, Solh, Melhem, Kharfan-Dabaja, Mohamed, Diaz, Miguel, Ganguly, Siddhartha, Gore, Steven, Verdonck, Leo, Hossain, Nasheed, Kekre, Natasha, Savani, Bipin, Byrne, Michael, Kanakry, Christopher, Cairo, Mitchell, Ciurea, Stefan, Schouten, Harry, Bredeson, Christopher, Munker, Reinhold, Lazarus, Hillard, Cahn, Jean-Yves, van Der Poel, Marjolein, Rizzieri, David, Yared, Jean, Freytes, Cesar, Cerny, Jan, Aljurf, Mahmoud, Palmisiano, Neil, Pawarode, Attaphol, Bacher, Vera, Grunwald, Michael, Nathan, Sunita, Wirk, Baldeep, Hildebrandt, Gerhard, Seo, Sachiko, Olsson, Richard, George, Biju, de Lima, Marcos, Hourigan, Christopher, Sandmaier, Brenda, Litzow, Mark, Kebriaei, Partow, Saber, Wael, and Weisdorf, Daniel

Subjects
AML, DRI, MDS, Myeloablative, RIC, Adult, Aged, Disease-Free Survival, Hematopoietic Stem Cell Transplantation, Humans, Leukemia, Myeloid, Acute, Middle Aged, Myelodysplastic Syndromes, Retrospective Studies, Transplantation Conditioning, Transplantation, Homologous
Abstract

Compared with reduced-intensity conditioning (RIC), myeloablative conditioning (MAC) is generally associated with lower relapse risk after allogeneic hematopoietic cell transplantation (HCT) for acute myelogenous leukemia (AML) and myelodysplastic syndromes (MDS). However, disease-specific risk factors in AML/MDS can further inform when MAC and RIC may yield differential outcomes. We analyzed HCT outcomes stratified by the Disease Risk Index (DRI) in 4387 adults (age 40 to 65 years) to identify the impact of conditioning intensity. In the low/intermediate-risk DRI cohort, RIC was associated with lower nonrelapse mortality (NRM) (hazard ratio [HR], .74; 95% confidence interval [CI], .62 to .88; P < .001) but significantly greater relapse risk (HR, 1.54; 95% CI, 1.35 to 1.76; P < .001) and thus inferior disease-free survival (DFS) (HR, 1.19; 95% CI, 1.07 to 1.33; P = .001). In the high/very high-risk DRI cohort, RIC was associated with marginally lower NRM (HR, .83; 95% CI, .68 to 1.00; P = .051) and significantly higher relapse risk (HR, 1.23; 95% CI, 1.08 to 1.41; P = .002), leading to similar DFS using either RIC or MAC. These data support MAC over RIC as the preferred conditioning intensity for patients with AML/MDS with low/intermediate-risk DRI, but with a similar benefit as RIC in high/very high-risk DRI. Novel MAC regimens with less toxicity could benefit all patients, but more potent antineoplastic approaches are needed for the high/very-high risk DRI group.

Published
2021

8. Impact of cytogenetic abnormalities on outcomes of adult Philadelphia-negative acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation: a study by the Acute Leukemia Working Committee of the Center for International Blood and Marrow Transplant Research

Author

Lazaryan, Aleksandr, Dolan, Michelle, Zhang, Mei-Jie, Wang, Hai-Lin, Kharfan-Dabaja, Mohamed A, Marks, David I, Bejanyan, Nelli, Copelan, Edward, Majhail, Navneet S, Waller, Edmund K, Chao, Nelson, Prestidge, Tim, Nishihori, Taiga, Kebriaei, Partow, Inamoto, Yoshihiro, Hamilton, Betty, Hashmi, Shahrukh K, Kamble, Rammurti T, Bacher, Ulrike, Hildebrandt, Gerhard C, Stiff, Patrick J, McGuirk, Joseph, Aldoss, Ibrahim, Beitinjaneh, Amer M, Muffly, Lori, Vij, Ravi, Olsson, Richard F, Byrne, Michael, Schultz, Kirk R, Aljurf, Mahmoud, Seftel, Matthew, Savoie, Mary Lynn, Savani, Bipin N, Verdonck, Leo F, Cairo, Mitchell S, Hossain, Nasheed, Bhatt, Vijaya Raj, Frangoul, Haydar A, Abdel-Azim, Hisham, Malki, Monzr Al, Munker, Reinhold, Rizzieri, David, Khera, Nandita, Nakamura, Ryotaro, Ringdén, Olle, van der Poel, Marjolein, Murthy, Hemant S, Liu, Hongtao, Mori, Shahram, De Oliveira, Satiro, Bolaños-Meade, Javier, Elsawy, Mahmoud, Barba, Pere, Nathan, Sunita, George, Biju, Pawarode, Attaphol, Grunwald, Michael, Agrawal, Vaibhav, Wang, Youjin, Assal, Amer, Caro, Paul Castillo, Kuwatsuka, Yachiyo, Seo, Sachiko, Ustun, Celalettin, Politikos, Ioannis, Lazarus, Hillard M, Saber, Wael, Sandmaier, Brenda M, De Lima, Marcos, Litzow, Mark, Bachanova, Veronika, Weisdorf, Daniel, and Committee of the CIBMTR, Acute Leukemia

Subjects
Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Oncology and Carcinogenesis, Rare Diseases, Pediatric Cancer, Transplantation, Childhood Leukemia, Hematology, Cancer, Pediatric, Stem Cell Research, Adult, Chromosome Aberrations, Hematopoietic Stem Cell Transplantation, Humans, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Retrospective Studies, Transplantation Conditioning, Transplantation, Homologous, Acute Leukemia Committee of the CIBMTR, Cardiorespiratory Medicine and Haematology, Immunology, Cardiovascular medicine and haematology
Abstract

Cytogenetic risk stratification at diagnosis has long been one of the most useful tools to assess prognosis in acute lymphoblastic leukemia (ALL). To examine the prognostic impact of cytogenetic abnormalities on outcomes after allogeneic hematopoietic cell transplantation, we studied 1731 adults with Philadelphia-negative ALL in complete remission who underwent myeloablative or reduced intensity/non-myeloablative conditioning transplant from unrelated or matched sibling donors reported to the Center for International Blood and Marrow Transplant Research. A total of 632 patients had abnormal conventional metaphase cytogenetics. The leukemia-free survival and overall survival rates at 5 years after transplantation in patients with abnormal cytogenetics were 40% and 42%, respectively, which were similar to those in patients with a normal karyotype. Of the previously established cytogenetic risk classifications, modified Medical Research Council-Eastern Cooperative Oncology Group score was the only independent prognosticator of leukemia-free survival (P=0.03). In the multivariable analysis, monosomy 7 predicted post-transplant relapse [hazard ratio (HR)=2.11; 95% confidence interval (95% CI): 1.04-4.27] and treatment failure (HR=1.97; 95% CI: 1.20-3.24). Complex karyotype was prognostic for relapse (HR=1.69; 95% CI: 1.06-2.69), whereas t(8;14) predicted treatment failure (HR=2.85; 95% CI: 1.35-6.02) and overall mortality (HR=3.03; 95% CI: 1.44-6.41). This large study suggested a novel transplant-specific cytogenetic scheme with adverse [monosomy 7, complex karyotype, del(7q), t(8;14), t(11;19), del(11q), tetraploidy/near triploidy], intermediate (normal karyotype and all other abnormalities), and favorable (high hyperdiploidy) risks to prognosticate leukemia-free survival (P=0.02). Although some previously established high-risk Philadelphia-negative cytogenetic abnormalities in ALL can be overcome by transplantation, monosomy 7, complex karyotype, and t(8;14) continue to pose significant risks and yield inferior outcomes.

Published
2020

9. Outcomes of haploidentical vs matched sibling transplantation for acute myeloid leukemia in first complete remission.

Author

Rashidi, Armin, Hamadani, Mehdi, Zhang, Mei-Jie, Wang, Hai-Lin, Abdel-Azim, Hisham, Aljurf, Mahmoud, Assal, Amer, Bajel, Ashish, Bashey, Asad, Battiwalla, Minoo, Beitinjaneh, Amer, Bejanyan, Nelli, Bhatt, Vijaya, Bolaños-Meade, Javier, Byrne, Michael, Cahn, Jean-Yves, Cairo, Mitchell, Ciurea, Stefan, Copelan, Edward, Cutler, Corey, Daly, Andrew, Diaz, Miguel-Angel, Farhadfar, Nosha, Gale, Robert, Ganguly, Siddhartha, Grunwald, Michael, Hahn, Theresa, Hashmi, Shahrukh, Hildebrandt, Gerhard, Holland, H, Hossain, Nasheed, Kanakry, Christopher, Kharfan-Dabaja, Mohamed, Khera, Nandita, Koc, Yener, Lazarus, Hillard, Lee, Jong-Wook, Maertens, Johan, Martino, Rodrigo, McGuirk, Joseph, Munker, Reinhold, Murthy, Hemant, Nakamura, Ryotaro, Nathan, Sunita, Nishihori, Taiga, Palmisiano, Neil, Patel, Sagar, Pidala, Joseph, Olin, Rebecca, Olsson, Richard, Oran, Betul, Ringden, Olov, Rizzieri, David, Rowe, Jacob, Savoie, Mary, Schultz, Kirk, Seo, Sachiko, Shaffer, Brian, Singh, Anurag, Solh, Melhem, Stockerl-Goldstein, Keith, Verdonck, Leo, Wagner, John, Waller, Edmund, De Lima, Marcos, Sandmaier, Brenda, Litzow, Mark, Weisdorf, Dan, Romee, Rizwan, and Saber, Wael

Subjects
Adolescent, Adult, Aged, Blood Donors, Bone Marrow Transplantation, Calcineurin Inhibitors, Chronic Disease, Cyclophosphamide, Disease-Free Survival, Female, Graft vs Host Disease, Hematopoietic Stem Cell Transplantation, Humans, Immunosuppressive Agents, Incidence, Leukemia, Myeloid, Acute, Male, Middle Aged, Recurrence, Remission Induction, Retrospective Studies, Siblings, Survival Analysis, Transplantation Conditioning, Transplantation, Haploidentical, Young Adult
Abstract

HLA-haploidentical hematopoietic cell transplantation (Haplo-HCT) using posttransplantation cyclophosphamide (PT-Cy) has improved donor availability. However, a matched sibling donor (MSD) is still considered the optimal donor. Using the Center for International Blood and Marrow Transplant Research database, we compared outcomes after Haplo-HCT vs MSD in patients with acute myeloid leukemia (AML) in first complete remission (CR1). Data from 1205 adult CR1 AML patients (2008-2015) were analyzed. A total of 336 patients underwent PT-Cy-based Haplo-HCT and 869 underwent MSD using calcineurin inhibitor-based graft-versus-host disease (GVHD) prophylaxis. The Haplo-HCT group included more reduced-intensity conditioning (65% vs 30%) and bone marrow grafts (62% vs 7%), consistent with current practice. In multivariable analysis, Haplo-HCT and MSD groups were not different with regard to overall survival (P = .15), leukemia-free survival (P = .50), nonrelapse mortality (P = .16), relapse (P = .90), or grade II-IV acute GVHD (P = .98). However, the Haplo-HCT group had a significantly lower rate of chronic GVHD (hazard ratio, 0.38; 95% confidence interval, 0.30-0.48; P < .001). Results of subgroup analyses by conditioning intensity and graft source suggested that the reduced incidence of chronic GVHD in Haplo-HCT is not limited to a specific graft source or conditioning intensity. Center effect and minimal residual disease-donor type interaction were not predictors of outcome. Our results indicate a lower rate of chronic GVHD after PT-Cy-based Haplo-HCT vs MSD using calcineurin inhibitor-based GVHD prophylaxis, but similar other outcomes, in patients with AML in CR1. Haplo-HCT is a viable alternative to MSD in these patients.

Published
2019

10. Maintenance therapy after second autologous hematopoietic cell transplantation for multiple myeloma. A CIBMTR analysis

Author

Pasvolsky, Oren, Yeshurun, Moshe, Fraser, Raphael, Estrada-Merly, Noel, Rozovski, Uri, Shargian-Alon, Liat, Assal, Amer, Banerjee, Rahul, Bumma, Naresh, Gale, Robert Peter, Hagen, Patrick, Holmberg, Leona, Hossain, Nasheed M., Lazarus, Hillard M., Lee, Cindy, Mian, Hira, Miller, Kevin C., Nathan, Sunita, Nagler, Arnon, Nishihori, Taiga, Parrondo, Ricardo D., Patel, Sagar, Schroeder, Mark A., Usmani, Saad Z., Wang, Trent, Wirk, Baldeep, Kumar, Shaji, Shah, Nina, Qazilbash, Muzaffar H., and D’Souza, Anita

Published
2022
Full Text
View/download PDF

11. Outcomes of Medicare-age eligible NHL patients receiving RIC allogeneic transplantation: a CIBMTR analysis.

Author

Shah, Nirav, Ahn, Kwang, Litovich, Carlos, Fenske, Timothy, Ahmed, Sairah, Battiwalla, Minoo, Bejanyan, Nelli, Dahi, Parastoo, Bolaños-Meade, Javier, Chen, Andy, Ciurea, Stefan, Bachanova, Veronika, DeFilipp, Zachariah, Epperla, Narendranath, Farhadfar, Nosha, Herrera, Alex, Haverkos, Bradley, Holmberg, Leona, Hossain, Nasheed, Kharfan-Dabaja, Mohamed, Kenkre, Vaishalee, Lazarus, Hillard, Murthy, Hemant, Nishihori, Taiga, Rezvani, Andrew, DSouza, Anita, Savani, Bipin, Ulrickson, Matthew, Waller, Edmund, Sureda, Anna, Smith, Sonali, and Hamadani, Mehdi

Subjects
Age Factors, Aged, Databases, Factual, Hematopoietic Stem Cell Transplantation, Humans, Lymphoma, Non-Hodgkin, Medicare, Middle Aged, Survival Analysis, Transplantation Conditioning, Transplantation, Homologous, United States
Abstract

The application of allogeneic hematopoietic cell transplantation (allo-HCT) in non-Hodgkin lymphoma (NHL) patients ≥65 years in the United States is limited by lack of Medicare coverage for this indication. Using the Center for International Blood and Marrow Transplant Research (CIBMTR) database, we report allo-HCT outcomes of NHL patients aged ≥65 years (older cohort; n = 446) compared with a cohort of younger NHL patients aged 55-64 years (n = 1183). We identified 1629 NHL patients undergoing a first reduced-intensity conditioning (RIC) or nonmyeloablative conditioning allo-HCT from 2008 to 2015 in the United States. Cord blood or haploidentical transplants were excluded. The median age was 68 years (range 65-77) for the older cohort vs 60 years (range 55-64) in the younger cohort. The 4-year adjusted probabilities of nonrelapse mortality (NRM), relapse/progression (R/P), progression-free survival (PFS), and overall survival (OS) of the younger and older groups were 24% vs 30% (P = .03), 41% vs 42% (P = .82), 37% vs 31% (P = .03), and 51% vs 46% (P = .07), respectively. Using multivariate analysis, compared with the younger group, the older cohort was associated with increased NRM, but there was no difference between the 2 cohorts in terms of R/P, PFS, or OS. The most common cause of death was disease relapse in both groups. In NHL patients eligible for allo-HCT, there was no difference in OS between the 2 cohorts. Age alone should not determine allo-HCT eligibility in NHL, and Medicare should expand allo-HCT coverage to older adults.

Published
2018

12. Interim Results of a Phase I/II Trial of Intermediate-Dose Post-Transplantation Cyclophosphamide after Reduced Intensity Conditioned HLA-Mismatched Bone Marrow Transplantation for Older or Unfit Patients

Author

McCurdy, Shannon R., primary, Hyder, Mustafa A., additional, Sabina, Ruby, additional, DeVries, Ashley, additional, Chalupa, Kirstin, additional, Berryman, Natasha, additional, Bernhardt, Jessica, additional, Cusmano, Alison Christina, additional, Chai, Amy, additional, Schwartz, Rebecca, additional, Dimitrova, Dimana, additional, Rechache, Kamil, additional, McKeown, Christi, additional, Stokes, Anita, additional, Sponaugle, Jennifer, additional, Frey, Noelle V., additional, Gill, Saar I., additional, Hexner, Elizabeth O, additional, Martin, Mary Ellen, additional, Hossain, Nasheed, additional, Porter, David L., additional, Loren, Alison W., additional, Kanakry, Jennifer A., additional, and Kanakry, Christopher G., additional

Published
2024
Full Text
View/download PDF

13. Post-Transplant Frailty Phenotype Predicts Survival

Author

Hadjis, Ashley D., primary, White, Griffin W., additional, Gill, Saar I., additional, Hossain, Nasheed, additional, Frey, Noelle V., additional, Hexner, Elizabeth O, additional, Bruno, Ximena Jordan, additional, Lai, Catherine E, additional, Matthews, Andrew H., additional, Martin, Mary Ellen, additional, Babushok, Daria V., additional, Perl, Alexander E., additional, Pratz, Keith W., additional, Luger, Selina M., additional, Porter, David L., additional, Loren, Alison W., additional, and McCurdy, Shannon R., additional

Published
2024
Full Text
View/download PDF

14. CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial

Author

Spiegel, Jay Y., Patel, Shabnum, Muffly, Lori, Hossain, Nasheed M., Oak, Jean, Baird, John H., and Frank, Matthew J.

Subjects
Antineoplastic agents -- Dosage and administration -- Testing, Lymphomas -- Care and treatment -- Diagnosis -- Development and progression, Antimitotic agents -- Dosage and administration -- Testing, Biological sciences, Health
Abstract

Despite impressive progress, more than 50% of patients treated with CD19-targeting chimeric antigen receptor T cells (CAR19) experience progressive disease. Ten of 16 patients with large B cell lymphoma (LBCL) with progressive disease after CAR19 treatment had absent or low CD19. Lower surface CD19 density pretreatment was associated with progressive disease. To prevent relapse with CD19.sup.- or CD19.sup.lo disease, we tested a bispecific CAR targeting CD19 and/or CD22 (CD19-22.BB.z-CAR) in a phase I clinical trial (NCT03233854) of adults with relapsed/refractory B cell acute lymphoblastic leukemia (B-ALL) and LBCL. The primary end points were manufacturing feasibility and safety with a secondary efficacy end point. Primary end points were met; 97% of products met protocol-specified dose and no dose-limiting toxicities occurred during dose escalation. In B-ALL (n = 17), 100% of patients responded with 88% minimal residual disease-negative complete remission (CR); in LBCL (n = 21), 62% of patients responded with 29% CR. Relapses were CD19.sup.-/lo in 50% (5 out of 10) of patients with B-ALL and 29% (4 out of 14) of patients with LBCL but were not associated with CD22.sup.-/lo disease. CD19/22-CAR products demonstrated reduced cytokine production when stimulated with CD22 versus CD19. Our results further implicate antigen loss as a major cause of CAR T cell resistance, highlight the challenge of engineering multi-specific CAR T cells with equivalent potency across targets and identify cytokine production as an important quality indicator for CAR T cell potency. Bispecific CAR T cells targeting CD19 and CD22 exhibit clinical activity and low toxicity in patients with large B cell lymphoma and B cell acute lymphoblastic leukemia, with relapses associated with loss of CD19 but not CD22., Author(s): Jay Y. Spiegel [sup.1] , Shabnum Patel [sup.2] , Lori Muffly [sup.1] [sup.2] , Nasheed M. Hossain [sup.3] , Jean Oak [sup.4] , John H. Baird [sup.1] , Matthew [...]

Published
2021
Full Text
View/download PDF

15. Severity of Chronic Graft-versus-Host Disease and Late Effects Following Allogeneic Hematopoietic Cell Transplantation for Adults with Hematologic Malignancy

Author

Lee, Catherine J., Wang, Tao, Chen, Karen, Arora, Mukta, Brazauskas, Ruta, Spellman, Stephen R., Kitko, Carrie, MacMillan, Margaret L., Pidala, Joseph A., Badawy, Sherif M., Bhatt, Neel, Bhatt, Vijaya R., DeFilipp, Zachariah, Diaz, Miguel A., Farhadfar, Nosha, Gadalla, Shahinaz, Hashmi, Shahrukh, Hematti, Peiman, Hossain, Nasheed M., Inamoto, Yoshihiro, Lekakis, Lazaros J., Sharma, Akshay, Solomon, Scott, Lee, Stephanie J., and Couriel, Daniel R.

Published
2024
Full Text
View/download PDF

16. Impact of depth of clinical response on outcomes of acute myeloid leukemia patients in first complete remission who undergo allogeneic hematopoietic cell transplantation

Author

Percival, Mary-Elizabeth, Wang, Hai-Lin, Zhang, Mei-Jie, Saber, Wael, de Lima, Marcos, Litzow, Mark, Kebriaei, Partow, Abdel-Azim, Hisham, Adekola, Kehinde, Aljurf, Mahmoud, Bacher, Ulrike, Badawy, Sherif M., Beitinjaneh, Amer, Bejanyan, Nelli, Bhatt, Vijaya, Byrne, Michael, Cahn, Jean-Yves, Castillo, Paul, Chao, Nelson, Chhabra, Saurabh, Copelan, Edward, Cutler, Corey, DeFilipp, Zachariah, Dias, Ajoy, Diaz, Miguel Angel, Estey, Elihu, Farhadfar, Nosha, Frangoul, Haydar A., Freytes, César O., Gale, Robert Peter, Ganguly, Siddhartha, Gowda, Lohith, Grunwald, Michael, Hossain, Nasheed, Kamble, Rammurti T., Kanakry, Christopher G., Kansagra, Ankit, Kharfan-Dabaja, Mohamed A., Krem, Maxwell, Lazarus, Hillard M., Lee, Jong Wook, Liesveld, Jane L., Lin, Richard, Liu, Hongtao, McGuirk, Joseph, Munker, Reinhold, Murthy, Hemant S., Nathan, Sunita, Nishihori, Taiga, Olsson, Richard F., Palmisiano, Neil, Passweg, Jakob R., Prestidge, Tim, Ringdén, Olov, Rizzieri, David A., Rybka, Witold B., Savoie, Mary Lynn, Schultz, Kirk R., Seo, Sachiko, Sharma, Akshay, Solh, Melhem, Strair, Roger, van der Poel, Marjolein, Verdonck, Leo F., Yared, Jean A., Weisdorf, Daniel, and Sandmaier, Brenda M.

Published
2021
Full Text
View/download PDF

17. Reduced intensity conditioning for acute myeloid leukemia using melphalan- vs busulfan-based regimens: a CIBMTR report

Author

Zhou, Zheng, Nath, Rajneesh, Cerny, Jan, Wang, Hai-Lin, Zhang, Mei-Jie, Abdel-Azim, Hisham, Agrawal, Vaibhav, Ahmed, Gulrayz, Al-Homsi, A. Samer, Aljurf, Mahmoud, Alkhateeb, Hassan B., Assal, Amer, Bacher, Ulrike, Bajel, Ashish, Bashir, Qaiser, Battiwalla, Minocher, Bhatt, Vijaya Raj, Byrne, Michael, Cahn, Jean-Yves, Cairo, Mitchell, Choe, Hannah, Copelan, Edward, Cutler, Corey, Damlaj, Moussab B., DeFilipp, Zachariah, De Lima, Marcos, Diaz, Miguel Angel, Farhadfar, Nosha, Foran, James, Freytes, César O., Gerds, Aaron T., Gergis, Usama, Grunwald, Michael R., Gul, Zartash, Hamadani, Mehdi, Hashmi, Shahrukh, Hertzberg, Mark, Hildebrandt, Gerhard C., Hossain, Nasheed, Inamoto, Yoshihiro, Isola, Luis, Jain, Tania, Kamble, Rammurti T., Khan, Muhammad Waqas, Kharfan-Dabaja, Mohamed A., Kebriaei, Partow, Kekre, Natasha, Khera, Nandita, Lazarus, Hillard M., Liesveld, Jane L., Litzow, Mark, Liu, Hongtao, Marks, David I., Martino, Rodrigo, Mathews, Vikram, Mishra, Asmita, Murthy, Hemant S., Nagler, Arnon, Nakamura, Ryotaro, Nathan, Sunita, Nishihori, Taiga, Olin, Rebecca, Olsson, Richard F., Palmisiano, Neil, Patel, Sagar S., Patnaik, Mrinal M., Pawarode, Attaphol, Perales, Miguel-Angel, Politikos, Ioannis, Popat, Uday, Rizzieri, David, Sandmaier, Brenda M., Savani, Bipin N., Seo, Sachiko, Shah, Nirav N., Uy, Geoffrey L., Valcárcel, David, Verdonck, Leo F., Waller, Edmund K., Wang, Youjin, Weisdorf, Daniel, Wirk, Baldeep, Wong, Eric, Yared, Jean A., and Saber, Wael

Published
2020
Full Text
View/download PDF

18. Maintenance Tyrosine Kinase Inhibitors Following Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Myelogenous Leukemia: A Center for International Blood and Marrow Transplant Research Study

Author

DeFilipp, Zachariah, Ancheta, Richard, Liu, Ying, Hu, Zhen-Huan, Gale, Robert Peter, Snyder, David, Schouten, Harry C., Kalaycio, Matt, Hildebrandt, Gerhard C., Ustun, Celalettin, Daly, Andrew, Ganguly, Siddhartha, Inamoto, Yoshihiro, Litzow, Mark, Szer, Jeffrey, Savoie, Mary Lynn, Hossain, Nasheed, Kharfan-Dabaja, Mohamed A., Hamadani, Mehdi, Reshef, Ran, Bajel, Ashish, Schultz, Kirk R., Gadalla, Shahinaz, Gerds, Aaron, Liesveld, Jane, Juckett, Mark B., Kamble, Rammurti, Hashmi, Shahrukh, Abdel-Azim, Hisham, Solh, Melhem, Bacher, Ulrike, Lazarus, Hillard, Olsson, Richard, Cahn, Jean-Yves, Grunwald, Michael R., Savani, Bipin N., Yared, Jean, Rowe, Jacob M., Cerny, Jan, Chaudhri, Naeem A., Aljurf, Mahmoud, Beitinjaneh, Amer, Seo, Sachiko, Nishihori, Taiga, Hsu, Jack W., Ramanathan, Muthalagu, Alyea, Edwin, Popat, Uday, Sobecks, Ronald, and Saber, Wael

Published
2020
Full Text
View/download PDF

19. Lower Graft-versus-Host Disease and Relapse Risk in Post-Transplant Cyclophosphamide–Based Haploidentical versus Matched Sibling Donor Reduced-Intensity Conditioning Transplant for Hodgkin Lymphoma

Author

Ahmed, Sairah, Kanakry, Jennifer A., Ahn, Kwang W., Litovich, Carlos, Abdel-Azim, Hisham, Aljurf, Mahmoud, Bacher, Vera Ulrike, Bejanyan, Nelli, Cohen, Jonathon B., Farooq, Umar, Fuchs, Ephraim J., Bolaños-Meade, Javier, Ghosh, Nilanjan, Herrera, Alex F., Hossain, Nasheed M., Inwards, David, Kanate, Abraham S., Martino, Rodrigo, Munshi, Pashna N., Murthy, Hemant, Mussetti, Alberto, Nieto, Yago, Perales, Miguel-Angel, Romee, Rizwan, Savani, Bipin N., Seo, Sachiko, Wirk, Baldeep, Yared, Jean A., Sureda, Ana, Fenske, Timothy S., and Hamadani, Mehdi

Published
2019
Full Text
View/download PDF

20. Severity of Chronic Graft-versus-Host Disease and Late Effects Following Allogeneic Hematopoietic Cell Transplantation for Adults with Hematologic Malignancy

Author

Lee, Catherine J., primary, Wang, Tao, additional, Chen, Karen, additional, Arora, Mukta, additional, Brazauskas, Ruta, additional, Spellman, Stephen R., additional, Kitko, Carrie, additional, MacMillan, Margaret L., additional, Pidala, Joseph A., additional, Badawy, Sherif M., additional, Bhatt, Neel, additional, Bhatt, Vijaya R., additional, DeFilipp, Zachariah, additional, Diaz, Miguel A., additional, Farhadfar, Nosha, additional, Gadalla, Shahinaz, additional, Hashmi, Shahrukh, additional, Hematti, Peiman, additional, Hossain, Nasheed M., additional, Inamoto, Yoshihiro, additional, Lekakis, Lazaros J., additional, Sharma, Akshay, additional, Solomon, Scott, additional, Lee, Stephanie J., additional, and Couriel, Daniel R., additional

Published
2023
Full Text
View/download PDF

21. Association of Chronic Graft-versus-Host Disease with Late Effects following Allogeneic Hematopoietic Cell Transplantation for Children with Hematologic Malignancy

Author

Lee, Catherine J., Wang, Tao, Chen, Karen, Arora, Mukta, Brazauskas, Ruta, Spellman, Stephen R., Kitko, Carrie, MacMillan, Margaret L., Pidala, Joseph A., Auletta, Jeffery J., Badawy, Sherif M., Bhatt, Neel, Bhatt, Vijaya R., Cahn, Jean-Yves, DeFilipp, Zachariah, Diaz, Miguel A., Farhadfar, Nosha, Gadalla, Shahinaz, Gale, Robert P., Hashem, Hasan, Hashmi, Shahrukh, Hematti, Peiman, Hong, Sanghee, Hossain, Nasheed M., Inamoto, Yoshihiro, Lekakis, Lazaros J., Modi, Dipenkumar, Patel, Sager, Sharma, Akshay, Solomon, Scott, and Couriel, Daniel R.

Published
2022
Full Text
View/download PDF

24. Maintenance versus Induction Therapy Choice on Outcomes after Autologous Transplantation for Multiple Myeloma

Author

Cornell, Robert F., D'Souza, Anita, Kassim, Adetola A., Costa, Luciano J., Innis-Shelton, Racquel D., Zhang, Mei-Jie, Huang, Jiaxing, Abidi, Muneer, Aiello, Jack, Akpek, Gorgun, Bashey, Asad, Bashir, Qaiser, Cerny, Jan, Comenzo, Raymond, Diaz, Miguel Angel, Freytes, César, Gale, Robert Peter, Ganguly, Siddhartha, Hamadani, Mehdi, Hashmi, Shahrukh, Holmberg, Leona, Hossain, Nasheed, Kamble, Rammurti T., Kharfan-Dabaja, Mohamed, Kindwall-Keller, Tamila, Kyle, Robert, Kumar, Shaji, Lazarus, Hillard, Lee, Cindy, Maiolino, Angelo, Marks, David I., Meehan, Kenneth, Mikhael, Joe, Nath, Rajneesh, Nishihori, Taiga, Olsson, Richard F., Ramanathan, Muthalagu, Saad, Ayman, Seo, Sachiko, Usmani, Saad, Vesole, David, Vij, Ravi, Vogl, Dan, Wirk, Baldeep M., Yared, Jean, Krishnan, Amrita, Mark, Tomer, Nieto, Yago, and Hari, Parameswaran

Published
2017
Full Text
View/download PDF

25. Correction to: Impact of depth of clinical response on outcomes of acute myeloid leukemia patients in first complete remission who undergo allogeneic hematopoietic cell transplantation

Author

Percival, Mary-Elizabeth, Wang, Hai-Lin, Zhang, Mei-Jie, Saber, Wael, de Lima, Marcos, Litzow, Mark, Kebriaei, Partow, Abdel-Azim, Hisham, Adekola, Kehinde, Aljurf, Mahmoud, Bacher, Ulrike, Badawy, Sherif M., Beitinjaneh, Amer, Bejanyan, Nelli, Bhatt, Vijaya, Byrne, Michael, Cahn, Jean-Yves, Castillo, Paul, Chao, Nelson, Chhabra, Saurabh, Copelan, Edward, Cutler, Corey, DeFilipp, Zachariah, Dias, Ajoy, Diaz, Miguel Angel, Estey, Elihu, Farhadfar, Nosha, Frangoul, Haydar A., Freytes, César O., Gale, Robert Peter, Ganguly, Siddhartha, Gowda, Lohith, Grunwald, Michael, Hossain, Nasheed, Kamble, Rammurti T., Kanakry, Christopher G., Kansagra, Ankit, Kharfan-Dabaja, Mohamed A., Krem, Maxwell, Lazarus, Hillard M., Lee, Jong Wook, Liesveld, Jane L., Lin, Richard, Liu, Hongtao, McGuirk, Joseph, Munker, Reinhold, Murthy, Hemant S., Nathan, Sunita, Nishihori, Taiga, Olsson, Richard F., Palmisiano, Neil, Passweg, Jakob R., Prestidge, Tim, Ringdén, Olov, Rizzieri, David A., Rybka, Witold B., Savoie, Mary Lynn, Schultz, Kirk R., Seo, Sachiko, Sharma, Akshay, Solh, Melhem, Strair, Roger, van der Poel, Marjolein, Verdonck, Leo F., Yared, Jean A., Weisdorf, Daniel, and Sandmaier, Brenda M.

Published
2021
Full Text
View/download PDF

26. Older patients with primary central nervous system lymphoma: Survival and prognostication across 20 U.S. cancer centers

Author

David, Kevin A., primary, Sundaram, Suchitra, additional, Kim, Seo‐Hyun, additional, Vaca, Ryan, additional, Lin, Yong, additional, Singer, Samuel, additional, Malecek, Mary‐Kate, additional, Carter, Jordan, additional, Zayac, Adam, additional, Kim, Myung Sun, additional, Reddy, Nishitha, additional, Ney, Douglas, additional, Habib, Alma, additional, Strouse, Christopher, additional, Graber, Jerome, additional, Bachanova, Veronika, additional, Salman, Sidra, additional, Vendiola, Jean Alyxa, additional, Hossain, Nasheed, additional, Tsang, Mazie, additional, Major, Ajay, additional, Bond, David A., additional, Agrawal, Prashasti, additional, Mier‐Hicks, Angel, additional, Torka, Pallawi, additional, Rajakumar, Priya, additional, Venugopal, Parameswaran, additional, Berg, Stephanie, additional, Glantz, Michael, additional, Goldlust, Samuel A., additional, Folstad, Matthew, additional, Kumar, Pallavi, additional, Ollila, Thomas A., additional, Cai, Johnny, additional, Spurgeon, Stephen, additional, Sieg, Alex, additional, Cleveland, Joseph, additional, Chang, Julie, additional, Epperla, Narendranath, additional, Karmali, Reem, additional, Naik, Seema, additional, Martin, Peter, additional, Smith, Sonali M., additional, Rubenstein, James, additional, Kahl, Brad, additional, and Evens, Andrew M., additional

Published
2023
Full Text
View/download PDF

29. C‐MYC–positive relapsed and refractory, diffuse large B‐cell lymphoma: Impact of additional “hits” and outcomes with subsequent therapy

Author

Epperla, Narendranath, Maddocks, Kami J., Salhab, Mohammed, Chavez, Julio C., Reddy, Nishitha, Karmali, Reem, Umyarova, Elvira, Bachanova, Veronika, Costa, Cristiana, Glenn, Martha, Calzada, Oscar, Xavier, Ana C., Zhou, Zheng, Hossain, Nasheed M., Hernandez‐Ilizaliturri, Francisco J., Al‐Mansour, Zeina, Barta, Stefan K., Chhabra, Saurabh, Lansigan, Frederick, Mehta, Amitkumar, Jaglal, Michael V., Evans, Andrew, Flowers, Christopher R., Cohen, Jonathon B., Fenske, Timothy S., Hamadani, Mehdi, and Costa, Luciano J.

Published
2017
Full Text
View/download PDF

32. COVID ‐19 Thromboembolism Incidence, Risk Factors and Anticoagulation Practices from a Chicago Metropolitan US Population

Author

Berg, Stephanie, primary, Kim, Seo‐Hyun, additional, Wozniak, Amy, additional, Odetola, Oluwatobi, additional, Arain, Saad, additional, Aleem, Ahmed, additional, Coggan, James, additional, Dave, Ami, additional, Elliott, Elizabeth, additional, Guerrettaz, Ryan, additional, Dalal, Hina, additional, Lee, Raymond, additional, Kodali, Abhigna, additional, Moore, Patrick, additional, Patel, Sonam, additional, Rajakumar, Priya, additional, Qin, Shuai, additional, Ramos, Glenda Delgado, additional, Schwartz, Candice, additional, Esmail, Fatema, additional, Feltman Frank, Rebecca, additional, Murchie, Ellen, additional, Pax, Laura, additional, Yun, Nicole, additional, Zhang, Yanyu, additional, Barton, Kevin, additional, Hagen, Patrick, additional, Hossain, Nasheed, additional, Larson, Melissa L., additional, Mai, Hanh, additional, Nand, Sucha, additional, Phelan, Kathleen, additional, Venugopal, Parameswawran, additional, Stiff, Patrick, additional, and Saraf, Santosh, additional

Published
2022
Full Text
View/download PDF

34. Relapse and Disease-Free Survival in Patients With Myelodysplastic Syndrome Undergoing Allogeneic Hematopoietic Cell Transplantation Using Older Matched Sibling Donors vs Younger Matched Unrelated Donors

Author

Guru Murthy, Guru Subramanian, primary, Kim, Soyoung, additional, Hu, Zhen-Huan, additional, Estrada-Merly, Noel, additional, Abid, Muhammad Bilal, additional, Aljurf, Mahmoud, additional, Bacher, Ulrike, additional, Badawy, Sherif M., additional, Beitinjaneh, Amer, additional, Bredeson, Chris, additional, Cahn, Jean-Yves, additional, Cerny, Jan, additional, Diaz Perez, Miguel Angel, additional, Farhadfar, Nosha, additional, Gale, Robert Peter, additional, Ganguly, Siddhartha, additional, Gergis, Usama, additional, Hildebrandt, Gerhard C., additional, Grunwald, Michael R., additional, Hashmi, Shahrukh, additional, Hossain, Nasheed M., additional, Kalaycio, Matt, additional, Kamble, Rammurti T., additional, Kharfan-Dabaja, Mohamed A., additional, Hamilton, Betty Ky, additional, Lazarus, Hillard M., additional, Liesveld, Jane, additional, Litzow, Mark, additional, Marks, David I., additional, Murthy, Hemant S., additional, Nathan, Sunita, additional, Nazha, Aziz, additional, Nishihori, Taiga, additional, Patel, Sagar S., additional, Pawarode, Attaphol, additional, Rizzieri, David, additional, Savani, Bipin, additional, Seo, Sachiko, additional, Solh, Melhem, additional, Ustun, Celalettin, additional, van der Poel, Marjolein, additional, Verdonck, Leo F., additional, Vij, Ravi, additional, Wirk, Baldeep, additional, Oran, Betul, additional, Nakamura, Ryotaro, additional, Scott, Bart, additional, and Saber, Wael, additional

Published
2022
Full Text
View/download PDF

35. Interim Results of a Phase I/II Study of Intermediate-Dose Post-Transplantation Cyclophosphamide after Reduced Intensity Conditioned HLA-Matched Bone Marrow Transplantation for Older or Infirm Patients

Author

Hyder, Mustafa A., McCurdy, Shannon R., Sabina, Ruby, DeVries, Ashley, Chalupa, Kirstin, Berryman, Natasha, Bernhardt, Jessica, Cusmano, Alison Christina, Chai, Amy, Schwartz, Rebecca, Dimitrova, Dimana, Rechache, Kamil, McKeown, Christi, Stokes, Anita, Sponaugle, Jennifer, Frey, Noelle V., Gill, Saar I., Hexner, Elizabeth O, Martin, Mary Ellen, Hossain, Nasheed, Porter, David L., Loren, Alison W., Kanakry, Jennifer A., and Kanakry, Christopher G.

Published
2024
Full Text
View/download PDF

36. Maintenance therapy after second autologous hematopoietic cell transplantation for multiple myeloma. A CIBMTR analysis

Author

Pasvolsky, Oren, primary, Yeshurun, Moshe, additional, Fraser, Raphael, additional, Estrada-Merly, Noel, additional, Rozovski, Uri, additional, Shargian-Alon, Liat, additional, Assal, Amer, additional, Banerjee, Rahul, additional, Bumma, Naresh, additional, Gale, Robert Peter, additional, Hagen, Patrick, additional, Holmberg, Leona, additional, Hossain, Nasheed M., additional, Lazarus, Hillard M., additional, Lee, Cindy, additional, Mian, Hira, additional, Miller, Kevin C., additional, Nathan, Sunita, additional, Nagler, Arnon, additional, Nishihori, Taiga, additional, Parrondo, Ricardo D., additional, Patel, Sagar, additional, Schroeder, Mark A., additional, Usmani, Saad Z., additional, Wang, Trent, additional, Wirk, Baldeep, additional, Kumar, Shaji, additional, Shah, Nina, additional, Qazilbash, Muzaffar H., additional, and D’Souza, Anita, additional

Published
2021
Full Text
View/download PDF

37. Monitoring of Circulating Tumor DNA Improves Early Relapse Detection After Axicabtagene Ciloleucel Infusion in Large B-Cell Lymphoma: Results of a Prospective Multi-Institutional Trial

Author

Frank, Matthew J., primary, Hossain, Nasheed M., additional, Bukhari, Ali, additional, Dean, Erin, additional, Spiegel, Jay Y., additional, Claire, Gursharan K., additional, Kirsch, Ilan, additional, Jacob, Allison P., additional, Mullins, Chelsea D., additional, Lee, Lik Wee, additional, Kong, Katherine A., additional, Craig, Juliana, additional, Mackall, Crystal L., additional, Rapoport, Aaron P., additional, Jain, Michael D., additional, Dahiya, Saurabh, additional, Locke, Frederick L., additional, and Miklos, David B., additional

Published
2021
Full Text
View/download PDF

39. Comparing Cairo Bishop and Howard Criteria for Identifying Clinically Meaningful Tumor Lysis Syndrome Among Acute Myeloid Leukemia Patients Treated with Venetoclax and Hypomethylating Agents: A Single Center Experience

Author

Rowe, Margaret, Babushok, Daria V, Carroll, Martin, Carulli, Alison, Frey, Noelle V., Gill, Saar, Hexner, Elizabeth O, Hirsh, Rebecca, Hossain, Nasheed, Lai, Catherine, Loren, Alison W, Luger, Selina M, Maillard, Ivan, McCurdy, Shannon R, Matthews, Andrew H, Martin, Mary Ellen, Paralkar, Vikram R, Perl, Alexander, Porter, David L., Pratz, Keith W, Stadtmauer, Edward A., and Jordan Bruno, Ximena

Published
2023
Full Text
View/download PDF

40. 42 - First Late Effect in Pediatric Survivors with Chronic Graft-Versus-Host Disease Following Hematopoietic Cell Transplantation for Hematologic Malignancy

Author

Lee, Catherine J., Wang, Tao, Chen, Karen, Spellman, Stephen R., Kitko, Carrie Lynn, MacMillan, Margaret L., Pidala, Joseph A., Auletta, Jeffery J., Badawy, Sherif, Battiwalla, Minoo, Bhatt, Vijaya Raj, Buchbinder, David, Cahn, Jean-Yves, DeFilipp, Zachariah, Diaz, Miguel Angel, Farhadfar, Nosha, Gadalla, Shahinaz M, Gale, Robert Peter, Hashem, Hasan, Hashmi, Shahrukh K., Hematti, Peiman, Hong, Sanghee, Hossain, Nasheed, Inamoto, Yoshihiro, Kamble, Rammurti T., Kumar, Anita, Lekakis, Lazaros J., Modi, Dipenkumar, Patel, Sagar, Savani, Bipin, Sharma, Akshay, Solomon, Scott R., Verdonck, Leo, Arora, Mukta, and Couriel, Daniel R.

Published
2021
Full Text
View/download PDF

42. Impact of Chronic Graft-Versus-Host Disease on First Late Effect Among Adult Survivors of Hematopoietic Cell Transplantation: A Center for International Blood and Marrow Transplant Research (CIBMTR) Analysis

Author

Lee, Catherine J., primary, Wang, Tao, additional, Chen, Karen, additional, Spellman, Stephen R., additional, Kitko, Carrie Lynn, additional, MacMillan, Margaret L., additional, Pidala, Joseph A., additional, Auletta, Jeffery J., additional, Badawy, Sherif, additional, Battiwalla, Minoo, additional, Bhatt, Vijaya Raj, additional, Buchbinder, David, additional, Cahn, Jean-Yves, additional, DeFilipp, Zachariah, additional, Diaz, Miguel Angel, additional, Farhadfar, Nosha, additional, Gadalla, Shahinaz M, additional, Gale, Robert Peter, additional, Hashem, Hasan, additional, Hashmi, Shahrukh K., additional, Hematti, Peiman, additional, Hong, Sanghee, additional, Hossain, Nasheed, additional, Inamoto, Yoshihiro, additional, Kamble, Rammurti T., additional, Kumar, Anita, additional, Lekakis, Lazaros J., additional, Modi, Dipenkumar, additional, Patel, Sagar, additional, Savani, Bipin, additional, Sharma, Akshay, additional, Solomon, Scott R., additional, Verdonck, Leo, additional, Arora, Mukta, additional, and Couriel, Daniel R., additional

Published
2021
Full Text
View/download PDF

43. First Late Effect in Pediatric Survivors with Chronic Graft-Versus-Host Disease Following Hematopoietic Cell Transplantation for Hematologic Malignancy

Author

Lee, Catherine J., primary, Wang, Tao, additional, Chen, Karen, additional, Spellman, Stephen R., additional, Kitko, Carrie Lynn, additional, MacMillan, Margaret L., additional, Pidala, Joseph A., additional, Auletta, Jeffery J., additional, Badawy, Sherif, additional, Battiwalla, Minoo, additional, Bhatt, Vijaya Raj, additional, Buchbinder, David, additional, Cahn, Jean-Yves, additional, DeFilipp, Zachariah, additional, Diaz, Miguel Angel, additional, Farhadfar, Nosha, additional, Gadalla, Shahinaz M, additional, Gale, Robert Peter, additional, Hashem, Hasan, additional, Hashmi, Shahrukh K., additional, Hematti, Peiman, additional, Hong, Sanghee, additional, Hossain, Nasheed, additional, Inamoto, Yoshihiro, additional, Kamble, Rammurti T., additional, Kumar, Anita, additional, Lekakis, Lazaros J., additional, Modi, Dipenkumar, additional, Patel, Sagar, additional, Savani, Bipin, additional, Sharma, Akshay, additional, Solomon, Scott R., additional, Verdonck, Leo, additional, Arora, Mukta, additional, and Couriel, Daniel R., additional

Published
2021
Full Text
View/download PDF

44. The Use of a Fitbit Physical Activity Monitor Device Among Patients Undergoing Hematopoietic Stem Cell Transplantation (HSCT)

Author

Mumby, Patricia B., primary, Thilges, Sarah, additional, Wesolowski, Michael, additional, Mooney, Sarah, additional, Davis, Allison, additional, Simmons, Elizabeth, additional, Smith, Scott E., additional, Hagen, Patrick A., additional, Tsai, Stephanie B., additional, Hossain, Nasheed, additional, Porter, Nancy, additional, and Stiff, Patrick, additional

Published
2021
Full Text
View/download PDF

46. Maintenance tyrosine kinase inhibitors following allo-HCT for chronic myeloid leukemia: A CIBMTR Study

Author

DeFilipp, Zachariah, Ancheta, Richard, Liu, Ying, Hu, Zhen-Huan, Gale, Robert Peter, Snyder, David, Schouten, Harry C, Kalaycio, Matt, Hildebrandt, Gerhard C, Ustun, Celalettin, Daly, Andrew, Ganguly, Siddhartha, Inamoto, Yoshihiro, Litzow, Mark, Szer, Jeffrey, Savoie, Mary Lynn, Hossain, Nasheed, Kharfan-Dabaja, Mohamed A, Hamadani, Mehdi, Reshef, Ran, Bajel, Ashish, Schultz, Kirk R, Gadalla, Shahinaz, Gerds, Aaron, Liesveld, Jane, Juckett, Mark B, Kamble, Rammurti, Hashmi, Shahrukh, Abdel-Azim, Hisham, Solh, Melhem, Bacher, Ulrike, Lazarus, Hillard, Olsson, Richard, Cahn, Jean-Yves, Grunwald, Michael R, Savani, Bipin N, Yared, Jean, Rowe, Jacob M, Cerny, Jan, Chaudhri, Naeem A, Aljurf, Mahmoud, Beitinjaneh, Amer, Seo, Sachiko, Nishihori, Taiga, Hsu, Jack W, Ramanathan, Muthalagu, Alyea, Edwin, Popat, Uday, Sobecks, Ronald, and Saber, Wael

Subjects
hemic and lymphatic diseases, 610 Medicine & health, respiratory tract diseases
Abstract

It remains unknown whether the administration of tyrosine kinase inhibitors (TKIs) targeting BCR-ABL1 after allogeneic hematopoietic cell transplantation (HCT) is associated with improved outcomes for patients with chronic myeloid leukemia (CML). In this registry study, we analyzed clinical outcomes of 390 adult patients with CML transplanted from 2007-2014 who received maintenance TKI following HCT (n=89) as compared to no TKI maintenance (n=301), as reported to the Center for International Blood and Marrow Transplant Research. All patients received TKI therapy prior to HCT. The majority of patients had disease beyond CP1 at HCT (n=240, 62%). The study was conducted as a landmark analysis, excluding patients that died, relapsed, had chronic graft-versus-host disease or were censored prior to Day 100 following HCT. Of the 89 patients receiving TKI maintenance, 77 (87%) received a single TKI while 12 (13%) received multiple sequential TKIs. The most common TKIs used for maintenance were dasatinib (n=50), imatinib (n=27) and nilotinib (n=27). As measured from Day 100, the adjusted estimates for 5-year relapse (maintenance, 35% vs. no maintenance, 26%; p=0.11), leukemia-free survival (LFS, maintenance, 42% vs. no maintenance, 44%; p=0.65) or overall survival (OS, maintenance, 61% vs. no maintenance, 57%; p=0.61) did not significantly differ between patients receiving TKI maintenance or no maintenance. These results remained unchanged in multivariate analysis and were not modified by the status of disease prior to transplant. In conclusion, our data did not demonstrate a significant impact of maintenance TKI therapy on clinical outcomes in a Day 100 landmark analysis. The optimal approach to TKI administration in the post-transplant setting in CML remains undetermined.

Published
2020

47. Outcomes of rituximab‐BEAM versus BEAM conditioning regimen in patients with diffuse large B cell lymphoma undergoing autologous transplantation

Author

Jagadeesh, Deepa, Majhail, Navneet S., He, Yizeng, Ahn, Kwang W., Litovich, Carlos, Ahmed, Sairah, Aljurf, Mahmoud, Bacher, Ulrike, Badawy, Sherif M., Bejanyan, Nelli, Cairo, Mitchell, Cerny, Jan, Epperla, Narendranath, Farhadfar, Nosha, Freytes, Cesar O., Gale, Robert Peter, Haverkos, Bradley, Hossain, Nasheed, Inwards, David, Kamble, Rammurti T., Kenkre, Vaishalee P., Lazarus, Hillard M., Lazaryan, Aleksandr, Lekakis, Lazaros, Mei, Matthew, Murthy, Hemant S., Mussetti, Alberto, Nathan, Sunita, Nishihori, Taiga, Olsson, Richard, Geethakumari, Praveen Ramakrishnan, Savani, Bipin N., Yared, Jean A., Fenske, Timothy S., Kharfan-Dabaja, Mohamed A., Sureda, Anna, Hamadani, Mehdi, Jagadeesh, Deepa, Majhail, Navneet S., He, Yizeng, Ahn, Kwang W., Litovich, Carlos, Ahmed, Sairah, Aljurf, Mahmoud, Bacher, Ulrike, Badawy, Sherif M., Bejanyan, Nelli, Cairo, Mitchell, Cerny, Jan, Epperla, Narendranath, Farhadfar, Nosha, Freytes, Cesar O., Gale, Robert Peter, Haverkos, Bradley, Hossain, Nasheed, Inwards, David, Kamble, Rammurti T., Kenkre, Vaishalee P., Lazarus, Hillard M., Lazaryan, Aleksandr, Lekakis, Lazaros, Mei, Matthew, Murthy, Hemant S., Mussetti, Alberto, Nathan, Sunita, Nishihori, Taiga, Olsson, Richard, Geethakumari, Praveen Ramakrishnan, Savani, Bipin N., Yared, Jean A., Fenske, Timothy S., Kharfan-Dabaja, Mohamed A., Sureda, Anna, and Hamadani, Mehdi

Abstract

BACKGROUND Although rituximab-based high-dose therapy is frequently used in diffuse large B cell lymphoma (DLBCL) patients undergoing autologous hematopoietic cell transplantation (auto-HCT), data supporting the benefits are not available. Herein, we report the impact of rituximab-based conditioning on auto-HCT outcomes in patients who have DLBCL. METHODS Using the Center for International Blood and Marrow Transplant Research (CIBMTR) registry, 862 adult DLBCL patients undergoing auto-HCT between 2003 and 2017 using BEAM (BCNU, etoposide, cytarabine, melphalan) conditioning regimen were included. All patients received frontline rituximab-containing chemoimmunotherapy and had chemosensitive disease pre-HCT. Early chemoimmunotherapy failure was defined as not achieving complete remission (CR) after frontline chemoimmunotherapy or relapse within 1 year of initial diagnosis. The primary outcome was overall survival (OS). RESULTS The study cohort was divided into 2 groups: BEAM (n = 667) and R-BEAM (n = 195). On multivariate analysis, no significant difference was seen in OS (P = .83) or progression-free survival (PFS) (P = .61) across the 2 cohorts. No significant association between the use of rituximab and risk of relapse (P = .15) or nonrelapse mortality (P = .12) was observed. Variables independently associated with lower OS included older age at auto-HCT (P < .001), absence of CR at auto-HCT (P < .001) and early chemoimmunotherapy failure (P < .001). Older age (P < .0002) and non-CR pre-HCT (P < .0001) were also associated with inferior PFS. There was no significant difference in early infectious complications between the 2 cohorts. CONCLUSION In this large registry analysis of DLBCL patients undergoing auto-HCT, the addition of rituximab to the BEAM conditioning regimen had no impact on transplantation outcomes. Older age, absence of CR pre auto-HCT, and early chemoimmunotherapy failure were associated with inferior survival.

Published
2020
Full Text
View/download PDF

48. Timing of allogeneic hematopoietic cell transplantation (alloHCT) for chronic myeloid leukemia (CML) patients

Author

Hu, Bei, Lin, Xiao, Lee, Hans C., Huang, Xuelin, Tidwell, Rebecca S. Slack, Ahn, Kwang Woo, Hu, Zhen-Huan, Jabbour, Elias, Verstovsek, Srdan, Ravandi, Farhad, Garcia-Manero, Guillermo, Kharfan-Dabaja, Mohamed A., Hossain, Nasheed M., Marks, David I., Kamble, Rammuriti T., Inamoto, Yoshihiro, Kindwall-Keller, Tamila, Saad, Ayman, Litzow, Mark R., Savani, Bipin N., Hale, Gregory A., Bacher, Ulrike, Gerds, Aaron T., Liesveld, Jane L., Ustun, Celalettin, Olsson, Richard, Daly, Andrew, Grunwald, Michael R., Solh, Melhem, DeFilipp, Zachariah, Aljurf, Mahmoud, Wirk, Baldeep, Akpek, Gorgun, Nishihori, Taiga, Cerny, Jan, Seo, Sachiko, Hsu, Jack W., Champlin, Richard, de Lima, Marcos, Alyea, Edwin, Popat, Uday, Sobecks, Ronald, Scott, Bart L., Kantarjian, Hagop, Cortes, Jorge, Saber, Wael, Hu, Bei, Lin, Xiao, Lee, Hans C., Huang, Xuelin, Tidwell, Rebecca S. Slack, Ahn, Kwang Woo, Hu, Zhen-Huan, Jabbour, Elias, Verstovsek, Srdan, Ravandi, Farhad, Garcia-Manero, Guillermo, Kharfan-Dabaja, Mohamed A., Hossain, Nasheed M., Marks, David I., Kamble, Rammuriti T., Inamoto, Yoshihiro, Kindwall-Keller, Tamila, Saad, Ayman, Litzow, Mark R., Savani, Bipin N., Hale, Gregory A., Bacher, Ulrike, Gerds, Aaron T., Liesveld, Jane L., Ustun, Celalettin, Olsson, Richard, Daly, Andrew, Grunwald, Michael R., Solh, Melhem, DeFilipp, Zachariah, Aljurf, Mahmoud, Wirk, Baldeep, Akpek, Gorgun, Nishihori, Taiga, Cerny, Jan, Seo, Sachiko, Hsu, Jack W., Champlin, Richard, de Lima, Marcos, Alyea, Edwin, Popat, Uday, Sobecks, Ronald, Scott, Bart L., Kantarjian, Hagop, Cortes, Jorge, and Saber, Wael

Abstract

While TKI are the preferred first-line treatment for chronic phase (CP) CML, alloHCT remains an important consideration. The aim is to estimate residual life expectancy (RLE) for patients initially diagnosed with CP CML based on timing of alloHCT or continuation of TKI in various settings: CP1 CML, CP2 + [after transformation to accelerated phase (AP) or blast phase (BP)], AP, or BP. Non-transplant cohort included single-institution patients initiating TKI and switched TKI due to failure. CIBMTR transplant cohort included CML patients who underwent HLA sibling matched (MRD) or unrelated donor (MUD) alloHCT. AlloHCT appeared to shorten survival in CP1 CML with overall mortality hazard ratio (HR) for alloHCT of 2.4 (95% CI 1.2-4.9;p = .02). In BP CML, there was a trend toward higher survival with alloHCT; HR = 0.7 (0.5-1.1;p = .099). AlloHCT in CP2 + [HR = 2.0 (0.8-4.9),p = .13] and AP [HR = 1.1 (0.6-2.1);p = .80] is less clear and should be determined on a case-by-case basis.

Published
2020
Full Text
View/download PDF

49. Real World Outcomes of Sars-Cov-2 Thrombosis Rates across Three University Health Systems in the Chicago Metropolitan Area

Author

Berg, Stephanie, primary, Kim, Seo-Hyun, additional, Patel, Sonam, additional, Rajakumar, Priya, additional, Elliott, Elizabeth Jane, additional, Schwartz, Candice, additional, Coggan, James, additional, Wozniak, Amy, additional, Zhang, Yanyu, additional, Arain, Saad, additional, Kodali, Abhigna, additional, Singh, Daulath, additional, Odetola, Oluwatobi, additional, Dalal, Hina, additional, Feltman Frank, Rebecca, additional, Kreppel, Diana, additional, Murchie, Ellen, additional, Pax, Laura, additional, Aleem, Ahmed, additional, Guerrettaz, Ryan, additional, Lee, Raymond W., additional, Delgado-Ramos, Glenda, additional, Esmail, Fatema, additional, Moore, Patrick, additional, Qin, Shuai, additional, Torgerson, Nicholas, additional, Watson, Tracie, additional, Barton, Kevin, additional, Hagen, Patrick, additional, Hossain, Nasheed, additional, Katsouli, Anthi, additional, Lowery, Erin M, additional, Larson, Melissa L., additional, Mai, Hanh, additional, Phelan, Katie W., additional, Nand, Sucha, additional, Stiff, Patrick J., additional, and Saraf, Santosh L., additional

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results